Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve presses ahead with quarter-point rate rise despite banking turmoil
    • Xi Jinping backs Vladimir Putin on Ukraine but holds out on Russian gas pipeline
    • Bundesbank chief says rate-setters must be ‘more stubborn’ in inflation fight
    • Ukraine hit by drone attacks as Russia accuses Kyiv of targeting Crimea
    • Russia alters oil taxes to capture bigger share of trades above price cap
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • What the takeover of Credit Suisse means for UBS
      • UBS to enter talks with Michael Klein to terminate First Boston deal
      • Indian data reveals Adani empire’s reliance on offshore funding
      • Wry humour, grief and Bear Grylls all on show at Credit Suisse conference
      • Switzerland bans deferred bonuses for Credit Suisse staff
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news: Lindsay Lohan, Jake Paul charged by SEC over Justin Sun crypto scheme
      • JPMorgan Asset Management chief warns on commercial real estate risks
      • Asia investors ‘gobsmacked’ by $17bn Credit Suisse bond wipeout
      • Credit Suisse fallout threatens to halt issuance of risky bank debt
      • Russia alters oil taxes to capture bigger share of trades above price cap
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A hefty shock awaits those who see little difference between Starmer and Sunak
      • It’s unwise to get Trump on a technicality
      • EY, KPMG and the fallout of two accounting scandals
      • Banker accountability is easier to demand than deliver
      • Four ways to fix the bank problem
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • From SVB to the BBC: why did no one see the crisis coming?
      • Football’s first female super-agent Rafaela Pimenta on dealmaking and discrimination
      • Social media content moderators lead charge for better rights
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The bleak beauty of Death Valley
      • Succession Season 4 puts the Roys on the brink of battle royal — review
      • Pack away the Peloton — Daylesford owner launches luxury health club
      • The kingdom of Sir Michael Kadoorie
      • The delectable daring of Herzog & de Meuron
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    AbbVie Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 24 February, 2023
      John Gapper
      The painfully high price of Humira is patently wrong

      Specialist drugs sold by Big Pharma are so expensive that many patients are being excluded

    • Tuesday, 21 February, 2023
      Drug prices
      AbbVie accused of overcharging Dutch for flagship drug Humira

      Drugmaker taken to court by public interest group for abusing market position and profiteering

    • Tuesday, 31 January, 2023
      Blockbuster AbbVie drug Humira to face competition in US for first time

      Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch

    • Monday, 16 January, 2023
      Drug prices
      US drugmakers withdraw from NHS pricing agreement as costs soar

      AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales

    • Wednesday, 6 May, 2020
      US regulator clears AbbVie’s $63bn deal for Allergan

      Federal Trade Commission votes 3-2 to approve tie-up between makers of Botox and Humira

    • Monday, 23 March, 2020
      Coronavirus pandemic
      AbbVie drops patent rights for Kaletra antiviral treatment

      Combination drug is being studied in several trials as a coronavirus treatment

    • Friday, 7 February, 2020
      AbbVie boosts outlook despite competition from generic drugs

      Quarterly earnings beat expectations as cancer drug sales jump

    • Thursday, 28 November, 2019
      Tail RiskJoe Rennison
      Why some corporate bond investors see higher risk in higher ratings

      Fund managers look for companies committed to protecting their balance sheet

    • Friday, 15 November, 2019
      Tail RiskJoe Rennison
      Credit market fears of downgrades have not materialised

      More supportive central bank policy has provided a prop as leveraged companies hold back

    • Tuesday, 12 November, 2019
      AbbVie sells $30bn of bonds to finance Allergan takeover

      Corporate issuance set to be among largest on record in US

    • Tuesday, 13 August, 2019
      Mergers & Acquisitions
      JPMorgan Chase set to scoop record fee for Allergan sale

      AbbVie’s planned $63bn purchase of the Botox-maker will earn $123m for bank

    • Friday, 26 July, 2019
      AbbVie raises guidance as cancer treatments boost sales

      Chicago-based pharmaceutical company reported better than expected earnings and revenue

    • Wednesday, 26 June, 2019
      News in-depth
      AbbVie hopes Botox-maker Allergan can iron out its wrinkles

      Pipeline failures and drugs coming off patent lead to tie-up of pharma companies

    • Tuesday, 25 June, 2019
      LexMergers & Acquisitions
      AbbVie/Allergan: not looking good Premium content

      Even desperate companies cannot count on shareholder support

    • Tuesday, 25 June, 2019
      AbbVie to acquire Botox maker Allergan for $63bn

      Cash and stock offer marks latest blockbuster deal in healthcare sector

    • Thursday, 25 April, 2019
      AbbVie raises forecasts despite pressure on Humira

      Blockbuster drug’s revenue outside US takes hit from new competition

    • Tuesday, 26 February, 2019
      Drug prices
      US drugmakers defend pricing under fire in Senate

      Some companies pledge to lower costs if government reforms rebate system

    • Sunday, 24 February, 2019
      News in-depthDrug prices
      Drugmakers face Senate over drug pricing

      Politicians to grill pharma executives over what is fast becoming a key election issue

    • Friday, 2 November, 2018
      LexPharmaceuticals sector
      AbbVie/arthritis drugs: copycat flap Premium content

      Pharm group’s patent loss will be the gain of healthcare funders

    • Sunday, 14 October, 2018
      News in-depthPharmaceuticals sector
      Rivals line up to take on world’s best-selling drug

      As the European patent on AbbVie’s Humira expires, biosimilars are ready to target $20bn market

    • Tuesday, 18 September, 2018
      Pharmaceuticals sector
      California sues AbbVie over alleged Humira kickbacks
    • Thursday, 26 April, 2018
      Pharmaceuticals sector
      AbbVie unveils $7.5bn share buyback

      Drugmaker’s quarterly earnings beat Wall Street expectations

    • Wednesday, 4 April, 2018
      News in-depthPharmaceuticals sector
      Investors smart at ailing pharma deals

      Doubts hang over acquisitions struck when the industry was in the grip of an M&A frenzy

    • Thursday, 22 March, 2018
      LexUS & Canadian companies
      AbbVie: getting over Rova Premium content

      Shareholders have lost faith after biotech titan failed to give substance to hype

    • Thursday, 22 March, 2018
      Pharmaceuticals sector
      AbbVie in $25bn wipeout after cancer drug results

      Pharma group’s shares fall by 11 per cent after lung cancer drug setback 

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In